Double-Blind Controlled Clinical Trial of Ancrod for Ischemic Rest Pain of the Leg

Lowe, G. D. O.; Dunlop, D. J.; Lawson, D. H.; Pollock, J. G.; Watt, J. K.; Forbes, C. D.; Prentice, C. R. M.; Drummond, M. M.
January 1982
Angiology;Jan1982, Vol. 33 Issue 1, p46
Academic Journal
In a randomized double-blind trial, patients with ischemic rest pain of the leg received 8 days of treatment with intravenous injections of the defibrinating agent, ancrod (Arvin) or saline. Plasma fibrinogen, plasma viscosity, and blood viscosity were significantly reduced during ancrod therapy. After 27 patients had completed treatment, sequential analysis showed no preference for either therapy. In each group two-thirds of the patients claimed improvement in pain after treatment. There were no significant differences between treatment groups in analgesic consumption, Doppler systolic pressure ratio, or surgical intervention in the 6 months following treatment. We conclude that in patients with ischemic rest pain, ancrod therapy is not superior to placebo injections, and that the effect of placebo treatment is considerable.


Related Articles

  • Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial. Lederer, David J.; Philip, Nisha; Rybak, Debbie; Arcasoy, Selim M.; Kawut, Steven M. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Background: We aimed to determine the effects of treatment with intravenous immunoglobulin on bacterial infections in patients with hypogammaglobulinemia (HGG) after lung transplantation. Methods: We performed a randomized, double-blind, placebo-controlled two-period crossover trial of immune...

  • ATLAS TIMI 46: Rivaroxaban did not lower endpoint of death, MI, stroke, severe ischemia requiring revascularization.  // Cardiology Today;Dec2008, Vol. 11 Issue 12, p19 

    The article focuses on the results of the phase-2 ATLAS TIMI 46 trial participated by 3,491 patients who were receiving either aspirin alone or aspirin plus clopidogrel who then received rivaroxaban once daily or twice daily at the same dosing levels or placebo. Results showed that rivaroxaban...

  • III. Fibrinogen concentrate: clinical reality and cautious Cochrane recommendation. Kozek-Langenecker, S.; Fries, D.; Spahn, D. R.; Zacharowski, K. // BJA: The British Journal of Anaesthesia;May2014, Vol. 112 Issue 5, p784 

    No abstract available.

  • Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand. Pitisuttithum, Punnee; Gilbert, Peter; Gurwith, Marc; Heyward, William; Martin, Michael; van Griensven, Fritz; Hu, Dale; Tappero, Jordan W.; Choopanya, Kachit // Journal of Infectious Diseases;12/15/2006, Vol. 194 Issue 12, p1661 

    Background. In Thailand, phase 1/2 trials of monovalent subtype B and bivalent subtype B/E (CRF01_AE) recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were successfully conducted from 1995 to 1998, prompting the first HIV-1 vaccine efficacy trial in Asia....

  • Aspirin and dipyridamole for the secondary prevention of stroke. Zielinski, Rafal; French, Linda // Journal of Family Practice;Feb1999, Vol. 48 Issue 2, p92 

    The article cites a research study that investigates whether low-dose acetylsalicylic acid (ASA) or modified-release dipyridamole are efficacious in secondary prevention of ischemic stroke. The Second European Stroke Prevention Study (ESPS-2) was a randomized double-blind clinical trial of...

  • The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men. Triesscheijn, Martijn; Ruevekamp, Marjan; Out, Ruud; Berkel, Theo J. C.; Schellens, Jan; Baas, Paul; Stewart, Fiona A. // Cancer Chemotherapy & Pharmacology;Jun2007, Vol. 60 Issue 1, p113 

    Meso-tetra-hydroxyphenyl-chlorin (mTHPC) is a hydrophobic photosensitizer that binds to plasma lipoproteins after intravenous injection. In vitro experiments with human plasma have shown that mTHPC initially binds to an unknown protein and subsequently redistributes to lipoprotein fractions. It...

  • Prohibit Placebo Controls? Ganter, Jane // Applied Clinical Trials;Sep2000, Vol. 9 Issue 9, p10 

    Comments on the use of placebo control in clinical trials for the treatment of life threatening disorders. Debate over the ethical issues of placebos; Application of the double standard thinking in placebos; Impact of the zero risk and tolerance demand on the debate resolution.

  • Case study: The placebo effect.  // Patient Care;9/15/2001, Vol. 35 Issue 17, p40 

    Provides information on a study which examined clinical trials comparing the treatment with placebo effect. Reliability of the clinical trials; Validity of the findings.

  • In Clinical Trials and In the Clinic, What Is the Placebo's Effect? Wang, Linda // JNCI: Journal of the National Cancer Institute;Jan2003, Vol. 95 Issue 1, p6 

    Reports on issues regarding the use of placebos in clinical trials. Relevant research on the placebo effect; Importance of placebo control in prevention studies; Use of placebo outside of clinical trials.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics